Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LO LOESTRIN FE vs LARIN 1.5/30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol and norethindrone acetate suppresses gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary, thereby inhibiting ovulation. The progestin component thickens cervical mucus, impeding sperm penetration, and alters endometrial receptivity. Ferrous fumarate provides supplemental iron.
Combination oral contraceptive: ethinyl estradiol suppresses FSH and LH, preventing ovulation; norethindrone induces endometrial changes and increases cervical mucus viscosity, impeding sperm penetration.
Oral contraception,Treatment of heavy menstrual bleeding (off-label),Dysmenorrhea (off-label),Acne vulgaris (off-label),Polycystic ovary syndrome (off-label)
Prevention of pregnancy
One tablet orally once daily. Each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 10 mcg (24 active tablets) followed by ferrous fumarate 75 mg (2 inactive tablets).
One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets.
Norethindrone: ~8 hours (range 5–12 h); Ethinyl estradiol: ~14 hours (range 10–20 h). Terminal half-life supports once-daily dosing with steady-state reached within 7–14 days.
Ethinyl estradiol: 13-19 hours; Norethindrone: 7-9 hours. Steady-state achieved in ~5-7 days.
Ethinyl estradiol is metabolized primarily via CYP3A4, with hydroxylation and conjugation pathways. Norethindrone acetate is rapidly hydrolyzed to norethindrone, which is metabolized via reduction and conjugation. Ferrous fumarate is absorbed and utilized for hemoglobin synthesis.
Ethinyl estradiol: primarily CYP3A4; norethindrone: primarily CYP3A4, with some reduction to active metabolites.
Renal (primarily as glucuronide conjugates of norethindrone and ethinyl estradiol): ~40% norethindrone metabolites, ~30% ethinyl estradiol metabolites; Fecal: ~30% norethindrone metabolites, ~40% ethinyl estradiol metabolites.
Renal (40% as metabolites, <10% unchanged); fecal (50% as metabolites); biliary (minor).
Norethindrone: ~61% bound (primarily to albumin and SHBG); Ethinyl estradiol: ~97–98% bound (primarily to albumin, with ~1–2% free).
Ethinyl estradiol: 97-98% bound to albumin; Norethindrone: 93-99% bound to SHBG and albumin.
Norethindrone: ~4 L/kg; Ethinyl estradiol: ~3–4 L/kg. Indicates extensive tissue distribution consistent with lipophilic steroids.
Ethinyl estradiol: 2.5-5 L/kg; Norethindrone: 2-4 L/kg. Indicates extensive tissue distribution.
Norethindrone: ~64% (oral); Ethinyl estradiol: ~45% (oral) due to first-pass metabolism, with high interindividual variability.
Oral: Ethinyl estradiol ~40-50% (first-pass metabolism); Norethindrone ~50-60% (first-pass metabolism).
No specific dosage adjustment required for renal impairment. Use with caution in patients with renal dysfunction due to potential fluid retention.
No dose adjustment required in mild to moderate renal impairment (Cr Cl >=30 m L/min). Use contraindicated in severe renal impairment (Cr Cl <30 m L/min) or renal failure due to potential for fluid retention and hyperkalemia.
Contraindicated in patients with hepatic impairment, including acute or chronic liver disease, hepatic adenomas, or impaired liver function. No adjustment guidelines available; do not use.
Contraindicated in Child-Pugh class B or C (moderate to severe hepatic impairment). For Child-Pugh class A, lowest possible effective dose should be used with close monitoring of liver function.
Not indicated for use before menarche. For post-menarchal adolescents, same dosing as adults: one tablet orally once daily.
Post-menarche adolescents: same dosing as adults (one tablet daily for 21 days, then 7 days placebo). Safety and efficacy in pre-menarche girls have not been established.
Not indicated for use in postmenopausal women. No specific dosing adjustments for elderly patients as the drug is not used in this population.
Not indicated for postmenopausal women. No specific geriatric dose adjustments; however, consider increased risk of thromboembolic events and cardiovascular disease in women aged >40 years who smoke or have other risk factors.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Increased risk of venous thromboembolism (VTE), myocardial infarction, and stroke, especially in smokers and women with hypertension or migraines,Adverse effects on bone density and potential for fractures with long-term use,Hepatic adenoma or hepatocellular carcinoma risk,Gallbladder disease,Glucose intolerance and insulin resistance,Elevated blood pressure,Cholestatic jaundice,Ocular lesions (e.g., retinal thrombosis),Depression,Iron overload in patients with hemochromatosis or chronic hemolytic anemia (due to ferrous fumarate)
Cardiovascular disease risk: smoking, hypertension, diabetes, hyperlipidemia,Thromboembolic events: increased risk in surgery, postpartum, or immobilization,Liver disease: discontinue if jaundice develops,Gallbladder disease: increased risk,Glucose intolerance: monitor in diabetics,Blood pressure elevation: monitor periodically,Depression: discontinue if severe
Current or history of thrombophlebitis, DVT, or thromboembolic disorders,Cerebrovascular or coronary artery disease,Known or suspected pregnancy,Undiagnosed abnormal uterine bleeding,Breast carcinoma or other hormone-sensitive cancer,Hepatic tumor (benign or malignant) or active liver disease,Hypersensitivity to any component,Smoking in women over 35,Hemochromatosis or chronic hemolytic anemia (due to ferrous fumarate)
Current or history of venous thromboembolism,Cerebrovascular or coronary artery disease,Uncontrolled hypertension,Diabetes with vascular involvement,Known or suspected pregnancy,Liver tumors or active liver disease,Undiagnosed abnormal uterine bleeding,Hypersensitivity to any component,Cigarette smoking in women over 35
No specific food interactions are known for Lo Loestrin Fe. However, grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects; it is prudent to advise against excessive grapefruit juice consumption. Iron tablets should be taken with food to reduce gastrointestinal upset; calcium-rich foods or supplements may decrease iron absorption, so separate iron intake from high-calcium meals by at least 2 hours.
Grapefruit juice may increase ethinyl estradiol levels; avoid excessive consumption. No specific dietary restrictions; can be taken with or without food.
Pregnancy category X. Contraindicated in pregnant women due to risk of fetal harm, including cardiovascular defects and neural tube defects. Use during first trimester associated with oral clefts; second and third trimester use may lead to fetal hyperbilirubinemia and jaundice.
First trimester: No consistent evidence of major malformations, but a small increased risk of cardiovascular defects and oral clefts cannot be excluded. Second and third trimesters: Associated with adverse fetal outcomes including low birth weight, preterm delivery, and neonatal withdrawal symptoms. Avoid use during pregnancy due to known risks.
Excreted in breast milk in small amounts; no reported adverse effects in infants. M/P ratio for ethinyl estradiol is approximately 0.04. Use with caution, especially during early postpartum period due to potential effects on milk production.
Small amounts of ethinyl estradiol and norethindrone transfer into breast milk, with a milk-to-plasma ratio approximately 0.2-0.3 for norethindrone and <0.1 for ethinyl estradiol. May reduce milk production and composition. Use caution and consider alternative contraception in nursing mothers.
Not applicable; drug is contraindicated in pregnancy. No dose adjustments recommended due to absence of safe therapeutic use.
Contraindicated in pregnancy; no dose adjustment is applicable as the drug should be discontinued immediately upon confirmed pregnancy.
Lo Loestrin Fe contains norethindrone acetate and ethinyl estradiol (1 mg/10 mcg) as the active hormonal pills, with a low iron (75 mg ferrous fumarate) supplement during the placebo week. It is the lowest-dose combination oral contraceptive available, which may minimize estrogen-related side effects. The regimen is 24 active pills, 2 placebo pills, then 2 iron pills, for a 28-day cycle. Spotting and breakthrough bleeding are common, especially in the first few cycles. It is indicated for contraception and not for emergency contraception. The iron tablets do not replace iron deficiency treatment. Contraindicated in patients with a history of thromboembolic disorders, liver disease, or known/suspected pregnancy.
Larin 1.5/30 is a monophasic combination oral contraceptive containing 1.5 mg norethindrone acetate and 30 mcg ethinyl estradiol. It is indicated for prevention of pregnancy and may also be used for management of acne and menstrual disorders. Advise patients to take at the same time daily to maintain consistent hormone levels. Counsel about breakthrough bleeding, especially during first cycles. Monitor for thrombotic events; use with caution in women with migraine with aura, hypertension, or smoking history over age 35. Effectiveness may be reduced with strong CYP3A4 inducers. Consider alternative contraception if patient is on chronic enzyme-inducing drugs. Use of NSAIDs can increase risk of breakthrough bleeding. Not recommended during breastfeeding or pregnancy.
Take one pill daily at the same time each day, preferably after the evening meal.,The first 24 pills are light blue (hormonal), the next 2 are white (placebo), and the last 2 are brown (iron tablets).,If you miss a dose: take it as soon as remembered, and if more than 12 hours late, use backup contraception for 7 days.,Common side effects: spotting, nausea, breast tenderness, and mood changes; these often improve after 3 months.,If you experience severe abdominal or chest pain, headache, or vision changes, seek medical attention.,Iron pills do not treat anemia; they only supplement daily iron needs.,Report any jaundice, depression, or high blood pressure to your healthcare provider.,Use an additional non-hormonal method if starting for the first time after the 5th day of your period.
Take one tablet at the same time each day, with or without food.,If you miss a dose, follow the instructions in the package insert; use backup contraception if needed.,Common side effects include nausea, breast tenderness, headache, and breakthrough bleeding, especially in the first few months.,Seek medical attention if you experience leg pain, chest pain, shortness of breath, severe headache, vision changes, or jaundice.,Do not smoke while taking this medication as it increases the risk of serious cardiovascular side effects.,Inform your healthcare provider of all medications you are taking, including over-the-counter drugs and supplements.,This medication does not protect against sexually transmitted infections; use condoms for STI prevention.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LO LOESTRIN FE vs LARIN 1.5/30, answered by our medical review team.
LO LOESTRIN FE is a Combination Oral Contraceptive that works by Combination of ethinyl estradiol and norethindrone acetate suppresses gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary, thereby inhibiting ovulation. The progestin component thickens cervical mucus, impeding sperm penetration, and alters endometrial receptivity. Ferrous fumarate provides supplemental iron.. LARIN 1.5/30 is a Combination Oral Contraceptive that works by Combination oral contraceptive: ethinyl estradiol suppresses FSH and LH, preventing ovulation; norethindrone induces endometrial changes and increases cervical mucus viscosity, impeding sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LO LOESTRIN FE and LARIN 1.5/30 depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LO LOESTRIN FE is: One tablet orally once daily. Each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 10 mcg (24 active tablets) followed by ferrous fumarate 75 mg (2 inactive tablets).. The standard adult dose of LARIN 1.5/30 is: One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LO LOESTRIN FE and LARIN 1.5/30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LO LOESTRIN FE is classified as Category C. Pregnancy category X. Contraindicated in pregnant women due to risk of fetal harm, including cardiovascular defects and neural tube defects. Use during first trimester associated w. LARIN 1.5/30 is classified as Category C. First trimester: No consistent evidence of major malformations, but a small increased risk of cardiovascular defects and oral clefts cannot be excluded. Second and third trimesters. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.